THE USE OF BOTULINUM TOXIN AND ITS ROLE IN PAIN MANAGEMENT- A SYSTEMATIC REVIEW

Małgorzata Słaboń; Karol Stępniak; Wojciech Gąska; Joanna Wrona; Daria Madycka; Kinga Wnuczek; Wiktor Telega; Weronika Skrzypek; Jędrzej Kęsik; Aleksandra Kaźmierczyk

doi:10.31435/ijitss.3(47).2025.3651

Małgorzata Słaboń 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland https://orcid.org/0000-0003-1627-8878
Karol Stępniak 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland https://orcid.org/0000-0002-8134-7967
Wojciech Gąska Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Poland https://orcid.org/0009-0005-7621-3533
Joanna Wrona 4th Clinical University Hospital in Lublin, Poland https://orcid.org/0009-0004-9267-1529
Daria Madycka University Clinical Hospital No. 1 in Lublin, Poland https://orcid.org/0000-0001-8682-1229
Kinga Wnuczek 4th Clinical University Hospital in Lublin, Poland https://orcid.org/0009-0001-6687-075X
Wiktor Telega 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland https://orcid.org/0009-0007-9805-243X
Weronika Skrzypek 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland https://orcid.org/0009-0004-3353-1390
Jędrzej Kęsik 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland https://orcid.org/0000-0001-8317-0213
Aleksandra Kaźmierczyk 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland https://orcid.org/0009-0007-7283-2518

DOI: https://doi.org/10.31435/ijitss.3(47).2025.3651

Keywords: Botulinum, Botulinum Toxin, Botulinum Toxin Type A, Migraine, Pelvic Pain, Trigeminal Neuralgia, Cluster Headache

Abstract

Introduction and Purpose: For many decades, botulinum toxin has been used in various fields of medicine, from aesthetic procedures to urology and neurology. It has become a highly effective and important therapeutic tool in the hands of a qualified physician. The aim of this article is to provide an overview of current research on the use of botulinum toxin in medicine, with a particular focus on its role in the treatment of various types of pain.

Materials and Methods: A literature review was conducted using the PubMed and Google Scholar databases. Relevant keywords were used as search terms.

Conclusion: Botulinum toxin, a neurotoxin with a good safety profile, is used in numerous branches of medicine and plays an increasingly important role in the treatment of various pain conditions. This review presents the current state of knowledge on the mechanism of action and analgesic properties of botulinum toxin and highlights its promising potential in the development of new therapeutic methods.

References

Nestor MS, Arnold D, Fischer DL. The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II. J Cosmet Dermatol. 2020 Nov;19(11):2785-2804. doi: 10.1111/jocd.13702. Epub 2020 Sep 16. Erratum in: J Cosmet Dermatol. 2021 Jun;20(6):1954. doi: 10.1111/jocd.14108. PMID: 32866999; PMCID: PMC7693297.

Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017 Apr;69(2):200-235. doi: 10.1124/pr.116.012658. PMID: 28356439; PMCID: PMC5394922.

Montecucco C, Molgó J. Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. doi: 10.1016/j.coph.2004.12.006. PMID: 15907915.

Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012 Oct;4(10):913-39. doi: 10.3390/toxins4100913. Epub 2012 Oct 19. PMID: 23162705; PMCID: PMC3496996.

Sadick NS. Botulinum toxin type B. Dermatol Surg. 2003 Apr;29(4):348-50; discussion 350-1. doi: 10.1046/j.1524-4725.2002.29083.x. PMID: 12656811.

Tighe AP, Schiavo G. Botulinum neurotoxins: mechanism of action. Toxicon. 2013 Jun 1;67:87-93. doi: 10.1016/j.toxicon.2012.11.011. Epub 2012 Nov 29. PMID: 23201505.

Kumar R, Singh BR. Botulinum Toxin: A Comprehensive Review of Its Molecular Architecture and Mechanistic Action. Int J Mol Sci. 2025 Jan 17;26(2):777. doi: 10.3390/ijms26020777. PMID: 39859491; PMCID: PMC11766063.

Choudhury S, Baker MR, Chatterjee S, Kumar H. Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. Toxins (Basel). 2021 Jan 14;13(1):58. doi: 10.3390/toxins13010058. PMID: 33466571; PMCID: PMC7828686.

Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arq Neuropsiquiatr. 2005 Mar;63(1):180-5. doi: 10.1590/s0004-282x2005000100035. Epub 2005 Apr 13. PMID: 15830090.

Tighe AP, Schiavo G. Botulinum neurotoxins: mechanism of action. Toxicon. 2013 Jun 1;67:87-93. doi: 10.1016/j.toxicon.2012.11.011. Epub 2012 Nov 29. PMID: 23201505.

Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm (Vienna). 2008;115(4):559-65. doi: 10.1007/s00702-007-0728-2. Epub 2007 Apr 26. PMID: 17458494.

Ayoub N. Botulinum Toxin Therapy: A Comprehensive Review on Clinical and Pharmacological Insights. J Clin Med. 2025 Mar 16;14(6):2021. doi: 10.3390/jcm14062021. PMID: 40142828; PMCID: PMC11943293.

Devriese PP. On the discovery of Clostridium botulinum. J Hist Neurosci. 1999 Apr;8(1):43-50. doi: 10.1076/jhin.8.1.43.1774. PMID: 11624135.

Hermjakob H, Montecchi-Palazzi L, Bader G, Wojcik J, Salwinski L, Ceol A, Moore S, Orchard S, Sarkans U, von Mering C, Roechert B, Poux S, Jung E, Mersch H, Kersey P, Lappe M, Li Y, Zeng R, Rana D, Nikolski M, Husi H, Brun C, Shanker K, Grant SG, Sander C, Bork P, Zhu W, Pandey A, Brazma A, Jacq B, Vidal M, Sherman D, Legrain P, Cesareni G, Xenarios I, Eisenberg D, Steipe B, Hogue C, Apweiler R. The HUPO PSI's molecular interaction format--a community standard for the representation of protein interaction data. Nat Biotechnol. 2004 Feb;22(2):177-83. doi: 10.1038/nbt926. PMID: 14755292.

Ceballos-Baumann A. Botulinum-toxin. Entwicklung zum anerkannten Medikament [Botulinum toxin. Development for therapeutic purposes]. Nervenarzt. 2008 Jun;79 Suppl 1:3-8. German. PMID: 18927957.

Jabbari B. History of Botulinum Toxin Treatment in Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2016 Nov 28;6:394. doi: 10.7916/D81836S1. PMID: 27917308; PMCID: PMC5133258.

Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10;86(19):1818-26. doi: 10.1212/WNL.0000000000002560. Epub 2016 Apr 18. PMID: 27164716; PMCID: PMC4862245.

Bach K, Simman R. The Multispecialty Toxin: A Literature Review of Botulinum Toxin. Plast Reconstr Surg Glob Open. 2022 Apr 6;10(4):e4228. doi: 10.1097/GOX.0000000000004228. PMID: 35402123; PMCID: PMC8987218.

Thant ZS, Tan EK. Emerging therapeutic applications of botulinum toxin. Med Sci Monit. 2003 Feb;9(2):RA40-8. PMID: 12601305.

Wen J, Nadora D, Ansari U, Syed B, Shehabat M, Razick DI, Razick AA, Rajagopal T. Exploring New and Potential Indications for Botulinum Toxin Treatment: An Updated Literature Review. Cureus. 2024 Dec 11;16(12):e75549. doi: 10.7759/cureus.75549. PMID: 39803022; PMCID: PMC11722663.

Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, Clarke CE, Sinclair A. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018 Jun 25;6(6):CD011616. doi: 10.1002/14651858.CD011616.pub2. PMID: 29939406; PMCID: PMC6513576.

Shankar Kikkeri N, Nagalli S. Migraine With Aura. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK554611/?utm_source=chatgpt.com

Dodick DW. Migraine. Lancet. 2018 Mar 31;391(10127):1315-1330. doi: 10.1016/S0140-6736(18)30478-1. Epub 2018 Mar 6. PMID: 29523342.

Turkel CC, Aurora S, Diener HC, Dodick DW, Lipton RB, Silberstein SD, Brin MF. Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 2023 Jul 1;102(S1):e32600. doi: 10.1097/MD.0000000000032600. PMID: 37499085; PMCID: PMC10374186.

Burstein R et al. The neurobiology of migraine. Cell. 2019;177(7):1714–30.

Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives NJ, Clarke CE, Sinclair AJ. Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine. BMJ Open. 2019 Jul 16;9(7):e027953. doi: 10.1136/bmjopen-2018-027953. PMID: 31315864; PMCID: PMC6661560.

Freitag FG, Diamond S, Diamond M, Urban G. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache. 2008 Feb;48(2):201-9. doi: 10.1111/j.1526-4610.2007.00963.x. Epub 2007 Nov 28. PMID: 18042229.

Shaterian N, Shaterian N, Ghanaatpisheh A, Abbasi F, Daniali S, Jahromi MJ, Sanie MS, Abdoli A. Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. Pain Res Manag. 2022 Mar 31;2022:3284446. doi: 10.1155/2022/3284446. PMID: 35401888; PMCID: PMC8989603.

Corasaniti MT, Bagetta G, Nicotera P, Tarsitano A, Tonin P, Sandrini G, Lawrence GW, Scuteri D. Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Toxins (Basel). 2023 May 12;15(5):332. doi: 10.3390/toxins15050332. PMID: 37235366; PMCID: PMC10223125.

Navarro-Pérez MP, González-Quintanilla V, Muñoz-Vendrell A, Madrigal E, Alpuente A, Latorre G, Molina F, Monzón MJ, Medrano V, García-Azorín D, González-Oria C, Gago-Veiga A, Velasco F, Beltrán I, Morollón N, Viguera J, Casas-Limón J, Rodríguez-Vico J, Cuadrado E, Irimia P, Iglesias F, Guerrero-Peral ÁL, Belvís R, Pozo-Rosich P, Pascual J, Santos-Lasaosa S. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study. Front Neurol. 2024 Jun 13;15:1417831. doi: 10.3389/fneur.2024.1417831. PMID: 38938776; PMCID: PMC11210495.

Freund B, Rao A. Efficacy of Botulinum Toxin in Tension-Type Headaches: A Systematic Review of the Literature. Pain Pract. 2019 Jun;19(5):541-551. doi: 10.1111/papr.12773. Epub 2019 Apr 22. PMID: 30742360.

Dhanasekara CS, Payberah D, Chyu JY, Shen CL, Kahathuduwa CN. The effectiveness of botulinum toxin for chronic tension-type headache prophylaxis: A systematic review and meta-analysis. Cephalalgia. 2023 Mar;43(3):3331024221150231. doi: 10.1177/03331024221150231. PMID: 36786349.

Ljubisavljevic S, Zidverc Trajkovic J. Cluster headache: pathophysiology, diagnosis and treatment. J Neurol. 2019 May;266(5):1059-1066. doi: 10.1007/s00415-018-9007-4. Epub 2018 Aug 17. PMID: 30120560.

Wei DY, Yuan Ong JJ, Goadsby PJ. Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and Diagnosis. Ann Indian Acad Neurol. 2018 Apr;21(Suppl 1):S3-S8. doi: 10.4103/aian.AIAN_349_17. PMID: 29720812; PMCID: PMC5909131.

Freund B, Kotchetkov IS, Rao A. The Efficacy of Botulinum Toxin in Cluster Headache: A Systematic Review. J Oral Facial Pain Headache. 2020 Spring;34(2):129–134. doi: 10.11607/ofph.2444. Epub 2019 Sep 27. PMID: 31560734.

Araya EI, Claudino RF, Piovesan EJ, Chichorro JG. Trigeminal Neuralgia: Basic and Clinical Aspects. Curr Neuropharmacol. 2020;18(2):109-119. doi: 10.2174/1570159X17666191010094350. PMID: 31608834; PMCID: PMC7324879.

Lambru G, Zakrzewska J, Matharu M. Trigeminal neuralgia: a practical guide. Pract Neurol. 2021 Oct;21(5):392-402. doi: 10.1136/practneurol-2020-002782. Epub 2021 Jun 9. PMID: 34108244; PMCID: PMC8461413.

Tereshko Y, Dal Bello S, Lettieri C, Belgrado E, Gigli GL, Merlino G, Valente M. Botulinum Toxin Type A for Trigeminal Neuralgia: A Comprehensive Literature Review. Toxins (Basel). 2024 Nov 20;16(11):500. doi: 10.3390/toxins16110500. PMID: 39591255; PMCID: PMC11597931.

Morra, M.E., Elgebaly, A., Elmaraezy, A. et al. Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials. J Headache Pain 17, 63 (2016). https://doi.org/10.1186/s10194-016-0651-8

Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC, Wang LJ. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012 Apr;32(6):443-50. doi: 10.1177/0333102412441721. Epub 2012 Apr 5. PMID: 22492424.

Hu X, Xia Y, Li J, Wang X, Liu H, Hu J, Bi J, Wu J, Wang T, Lin Z, Xiong N. Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Trigeminal Neuralgia: An Update on Systematic Review With Meta-analyses. Clin J Pain. 2024 Jun 1;40(6):383-392. doi: 10.1097/AJP.0000000000001207. PMID: 38385501.

Zondervan, K. T., Yudkin, P. L., Vessey, M. P., Jenkinson, C. P., Dawes, M. G., Barlow, D. H., & Kennedy, S. H. (2001). The community prevalence of chronic pelvic pain in women and associated illness behaviour. The British journal of general practice : the journal of the Royal College of General Practitioners, 51(468), 541–547.

Juganavar A, Joshi KS. Chronic Pelvic Pain: A Comprehensive Review. Cureus. 2022;14(10):e30691. Published 2022 Oct 26. doi:10.7759/cureus.30691

Mooney SS, Readman E, Hiscock RJ, Francis A, Fraser E, Ellett L. Botulinum toxin A (Botox) injection into muscles of pelvic floor as a treatment for persistent pelvic pain secondary to pelvic floor muscular spasm: A pilot study. Aust N Z J Obstet Gynaecol. 2021;61(5):777-784. doi:10.1111/ajo.13396

Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006;108(4):915-923. doi:10.1097/01.AOG.0000237100.29870.cc

Pastore EA, Katzman WB. Recognizing myofascial pelvic pain in the female patient with chronic pelvic pain. J Obstet Gynecol Neonatal Nurs. 2012;41(5):680-691. doi:10.1111/j.1552-6909.2012.01404.x

Jha S, Toozs-Hobson P, Roper JC, Gurung S, Brair A, Bach F. Botulinum injections for myofascial pelvic pain. Int Urogynecol J. 2021;32(5):1151-1156. doi:10.1007/s00192-020-04435-w

Sethi N, Singh S, DeBoulle K, Rahman E. A Review of Complications Due to the Use of Botulinum Toxin A for Cosmetic Indications. Aesthetic Plast Surg. 2021;45(3):1210-1220. doi:10.1007/s00266-020-01983-w

Satriyasa B. K. (2019). Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect. Clinical, cosmetic and investigational dermatology, 12, 223–228. https://doi.org/10.2147/CCID.S202919

Biello A, Zhu B. Botulinum Toxin Treatment of the Upper Face. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK574523/?utm_source=chatgpt.com

Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53(3):407-415. doi:10.1016/j.jaad.2005.06.011

Charles D, Brashear A, Hauser RA, et al. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol. 2012;35(5):208-214. doi:10.1097/WNF.0b013e31826538c7

Rahman E, Banerjee PS, Asghar A, Gupta NK, Mosahebi A. Botulinum Toxin Type A Immunogenicity across Multiple Indications: An Overview Systematic Review. Plast Reconstr Surg. 2022;149(4):837-848. doi:10.1097/PRS.0000000000008904

Sundaram, H., Signorini, M., Liew, S., Trindade de Almeida, A. R., Wu, Y., Vieira Braz, A., Fagien, S., Goodman, G. J., Monheit, G., Raspaldo, H., & Global Aesthetics Consensus Group (2016). Global Aesthetics Consensus: Botulinum Toxin Type A--Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plastic and reconstructive surgery, 137(3), 518e–529e. https://doi.org/10.1097/01.prs.0000475758.63709.23